Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05858619 · ClinicalTrials.gov registry record · Phase 4
Molecular Signatures of Cutaneous Dupilumab Response
A Phase 4 study of Atopic Dermatitis, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05858619 is a Phase 4 study of Atopic Dermatitis that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 15 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05858619, a Phase 4 study of Atopic Dermatitis, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2026-02-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05858619
The ClinicalTrials.gov registry entry for NCT05858619 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (98% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT05858619 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05858619 about?
NCT05858619 is a clinical study titled "Molecular Signatures of Cutaneous Dupilumab Response". This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
What is the current status of trial NCT05858619?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2023-02-01. Estimated completion is 2026-02-01.
What conditions does trial NCT05858619 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05858619?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT05858619?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05858619 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
RECRUITING · Phase 4
-
Ethnic Differences in Mechanisms of Action of Dupilumab
RECRUITING · Phase 4
-
Dupixent and Narrowband UVB for Atopic Dermatitis
RECRUITING · Phase 4
-
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 4
-
Dupilumab De-escalation in Pediatric Atopic Dermatitis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.